Niagen Bioscience, Inc. (NAGE) – What Are Investment Firms Saying About This Stock?

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have earned an average rating of “Buy” from the five brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $10.33.

NAGE has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Finally, Freedom Capital upgraded shares of Niagen Bioscience to a “strong-buy” rating in a report on Monday, July 6th.

Niagen Bioscience Stock Performance

Shares of Niagen Bioscience stock opened at $2.43 on Monday. The firm has a market capitalization of $193.53 million, a price-to-earnings ratio of 13.50 and a beta of 2.02. Niagen Bioscience has a fifty-two week low of $2.42 and a fifty-two week high of $7.95. The stock has a 50 day moving average of $2.92 and a 200 day moving average of $3.46.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analysts’ expectations of $29.95 million. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. Analysts forecast that Niagen Bioscience will post 0.10 EPS for the current year.

Institutional Investors Weigh In On Niagen Bioscience

A number of institutional investors have recently made changes to their positions in the stock. Stoneridge Investment Partners LLC purchased a new stake in shares of Niagen Bioscience in the 2nd quarter valued at approximately $49,000. Abel Hall LLC purchased a new position in shares of Niagen Bioscience during the 3rd quarter worth approximately $99,000. Teton Advisors LLC boosted its position in shares of Niagen Bioscience by 20.0% during the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock worth $132,000 after purchasing an additional 5,000 shares during the period. Chicago Partners Investment Group LLC purchased a new position in shares of Niagen Bioscience during the 1st quarter worth approximately $214,000. Finally, Quantinno Capital Management LP increased its holdings in Niagen Bioscience by 90.0% in the 1st quarter. Quantinno Capital Management LP now owns 50,946 shares of the company’s stock valued at $225,000 after purchasing an additional 24,135 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.